Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Marker Therapeutics, Inc. (MRKR)

0.3212   0.014 (4.59%) 11-25 12:47
Open: 0.2972 Pre. Close: 0.3071
High: 0.3264 Low: 0.2901
Volume: 48,670 Market Cap: 27(M)

Technical analysis

as of: 2022-11-25 1:58:53 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.47     One year: 0.56
Support: Support1: 0.28    Support2: 0.23
Resistance: Resistance1: 0.4    Resistance2: 0.47
Pivot: 0.36
Moving Average: MA(5): 0.31     MA(20): 0.37
MA(100): 0.37     MA(250): 0.46
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 14     %D(3): 12.3
RSI: RSI(14): 35.5
52-week: High: 1.25  Low: 0.25
Average Vol(K): 3-Month: 512 (K)  10-Days: 283 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MRKR ] has closed above bottom band by 17.4%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.33 - 0.33 0.33 - 0.33
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.3 - 0.31 0.31 - 0.31

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Headline News

Tue, 22 Nov 2022
Marker Therapeutics (MRKR) Announces FDA Clearance of IND for MT-601 - StreetInsider.com

Thu, 10 Nov 2022
Marker Therapeutics Reports Q3 2022 Operating and Financial Results - Yahoo Finance

Mon, 31 Oct 2022
BJP cancelled Adani’s coal deal, awarded it to Komatireddy: Congress - The New Indian Express

Thu, 20 Oct 2022
MARKER THERAPEUTICS, INC. : Termination of a Material Definitive Agreement (form 8-K) - Marketscreener.com

Tue, 04 Oct 2022
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely - Simply Wall St

Tue, 13 Sep 2022
MRKR stock gains on $2M FDA grant for leukemia candidate (NASDAQ:MRKR) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 84 (M)
Shares Float 60 (M)
% Held by Insiders 20.2 (%)
% Held by Institutions 25 (%)
Shares Short 1,190 (K)
Shares Short P.Month 1,170 (K)

Stock Financials

EPS -0.52
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin (%) 0
Operating Margin (%) -516.3
Return on Assets (ttm) -39.7
Return on Equity (ttm) -95.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.32
Sales Per Share 0.08
EBITDA (p.s.) -0.4
Qtrly Earnings Growth 0
Operating Cash Flow -26 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.61
PEG Ratio 0
Price to Book value 1.15
Price to Sales 3.76
Price to Cash Flow -1.03

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-09-15
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.